Inchakalody Varghese P, Hydrose Shereena P, Krishnankutty Roopesh, Merhi Maysaloun, Therachiyil Lubna, Sasidharan Nair Varun, Elashi Asma A, Khan Abdul Q, Taleb Sara, Raza Afsheen, Yoosuf Zeenath Safira K M, Fernandes Queenie, Al-Zaidan Lobna, Mestiri Sarra, Taib Nassiba, Bedhiafi Takwa, Moustafa Dina, Assami Laila, Maalej Karama Makni, Elkord Eyad, Uddin Shahab, Al Homsi Ussama, Dermime Said
National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Translational Cancer Research Facility, Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Eur J Pharmacol. 2023 Apr 15;945:175612. doi: 10.1016/j.ejphar.2023.175612. Epub 2023 Feb 22.
Dysregulated epigenetic modifications are common in lung cancer but have been reversed using demethylating agent like 5-Aza-CdR. 5-Aza-CdR induces/upregulates the NY-ESO-1 antigen in lung cancer. Therefore, we investigated the molecular mechanisms accompanied with the epigenetic regulation of NY-ESO-1 in 5-Aza-CdR-treated NCI-H1975 cell line. We showed significant induction of the NY-ESO-1 protein (**p < 0.0097) using Cellular ELISA. Bisulfite-sequencing demonstrated 45.6% demethylation efficiency at the NY-ESO-1 gene promoter region and RT-qPCR analysis confirmed the significant induction of NY-ESO-1 at mRNA level (128-fold increase, *p < 0.050). We then investigated the mechanism by which 5-Aza-CdR inhibits cell proliferation in the NCI-H1975 cell line. Upregulation of the death receptors TRAIL (2.04-fold *p < 0.011) and FAS (2.1-fold *p < 0.011) indicate activation of the extrinsic apoptotic pathway. The upregulation of Voltage-dependent anion-selective channel protein 1 (1.9-fold), Major vault protein (1.8-fold), Bax (1.16-fold), and Cytochrome C (1.39-fold) indicate the activation of the intrinsic pathway. We also observed the differential expression of protein Complement C3 (3.3-fold), Destrin (-5.1-fold), Vimentin (-1.7-fold), Peroxiredoxin 4 (-1.6-fold), Fascin (-1.8-fold), Heme oxygenase-2 (-0.67-foldp < 0.0055), Hsp27 (-0.57-foldp < 0.004), and Hsp70 (-0.39-fold **p < 0.001), indicating reduced cell growth, cell migration, and metastasis. The upregulation of 40S ribosomal protein S9 (3-fold), 40S ribosomal protein S15 (4.2-fold), 40S ribosomal protein S18 (2.5-fold), and 60S ribosomal protein L22 (4.4-fold) implied the induction of translation machinery. These results reiterate the decisive role of 5-Aza-CdR in lung cancer treatment since it induces the epigenetic regulation of NY-ESO-1 antigen, inhibits cell proliferation, increases apoptosis, and decreases invasiveness.
失调的表观遗传修饰在肺癌中很常见,但使用5-氮杂-2'-脱氧胞苷(5-Aza-CdR)等去甲基化剂可使其逆转。5-Aza-CdR可诱导/上调肺癌中的NY-ESO-1抗原。因此,我们研究了在5-Aza-CdR处理的NCI-H1975细胞系中,伴随NY-ESO-1表观遗传调控的分子机制。我们通过细胞酶联免疫吸附测定法显示NY-ESO-1蛋白有显著诱导(*p < 0.0097)。亚硫酸氢盐测序表明NY-ESO-1基因启动子区域的去甲基化效率为45.6%,逆转录定量聚合酶链反应(RT-qPCR)分析证实NY-ESO-1在mRNA水平有显著诱导(增加128倍,*p < 0.050)。然后我们研究了5-Aza-CdR抑制NCI-H1975细胞系中细胞增殖的机制。死亡受体肿瘤坏死因子相关凋亡诱导配体(TRAIL)上调(2.04倍,*p < 0.011)和FAS上调(2.1倍,*p < 0.011)表明外源性凋亡途径被激活。电压依赖性阴离子选择性通道蛋白1上调(1.9倍)、主要穹窿蛋白上调(1.8倍)、Bax上调(1.16倍)和细胞色素C上调(1.39倍)表明内源性途径被激活。我们还观察到补体C3蛋白(3.3倍)、肌动蛋白解聚因子(-5.1倍)、波形蛋白(-1.7倍)、过氧化物酶体增殖物激活受体4(-1.6倍)、成束蛋白(-1.8倍)、血红素加氧酶-2(-0.67倍p < 0.0055)、热休克蛋白27(-0.57倍p < 0.004)和热休克蛋白70(-0.39倍*p < 0.001)的差异表达,表明细胞生长、细胞迁移和转移减少。40S核糖体蛋白S9上调(3倍)、40S核糖体蛋白S15上调(4.2倍)、40S核糖体蛋白S18上调(